

Certificate of Analysis

Print Date: Sep 22nd 2023

www.tocris.com

Product Name: SB 525334 Catalog No.: 3211 Batch No.: 5

CAS Number: 356559-20-1

IUPAC Name: 6-[2-(1,1-Dimethylethyl)-5-(6-methyl-2-pyridinyl)-1*H*-imidazol-4-yl]quinoxaline

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: $C_{21}H_{21}N_5.\frac{1}{2}H_2O$

Batch Molecular Weight: 352.43

Physical Appearance: Yellow solid

Solubility: DMSO to 100 mM Storage: Store at -20°C

Batch Molecular Structure:

2. ANALYTICAL DATA

HPLC: Shows 99.3% purity

¹H NMR: Consistent with structure

Mass Spectrum: Consistent with structure

Microanalysis:

Carbon Hydrogen Nitrogen

Theoretical 71.57 6.29 19.87 Found 71.11 6.18 19.89

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use



Product Information

Print Date: Sep 22nd 2023

www.tocris.com

Product Name: Catalog No.: 3211 5 SB 525334

CAS Number: 356559-20-1

IUPAC Name: 6-[2-(1,1-Dimethylethyl)-5-(6-methyl-2-pyridinyl)-1*H*-imidazol-4-yl]quinoxaline

Description:

SB 525334 is a selective inhibitor of transforming growth factor-β receptor I (ALK5, TGF-βRI) (IC₅₀ = 14.3 nM). Inhibits TGF-β1induced smad2/3 nuclear localization and TGF-βRI-induced mRNA expression in kidney cells. Attenuates bleomycin-induced pulmonary fibrosis.

Physical and Chemical Properties:

Batch Molecular Formula: C₂₁H₂₁N₅.½H₂O

Batch Molecular Weight: 352.43 Physical Appearance: Yellow solid

Minimum Purity: ≥97%

Batch Molecular Structure:

Storage: Store at -20°C

Solubility & Usage Info:

DMSO to 100 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. *Unless contradicted by product-specific protocols or instructions, our standard recommendations apply:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

Licensing Information:

Sold with the permission of GlaxoSmithKline

References:

Higashiyama et al (2007) Inhibition of AVNreceptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis Exp.Mol.Pathol. 83 39. PMID: 17274978.

Laping et al (2007) Tumor-specific efficacy of transforming growth factor-BRI inhibition in eker rats. Clin.Cancer Res. 13 3087. PMID: 17505012.

Grygielko et al (2005) Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-β type I receptor kinase in puromycin-induced nephritis. J.Pharmacol.Exp.Ther. 313 943. PMID: 15769863.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use